<DOC>
	<DOCNO>NCT01678313</DOCNO>
	<brief_summary>To investigate therapeutic effect safety celecoxib add doxazosin potential predictive value absence prostate cancer treatment patient LUTS/BPH elevate serum PSA level . Patients meet eligible requirement entry study randomize one two treatment group 3 month 2:1 ratio show : 1 . Doxazosin 4 mg daily plus celecoxib 200 mg every day ( QD ) 2 . Doxazosin 4mg every day ( QD )</brief_summary>
	<brief_title>Cyclooxygenase-2 ( COX-2 ) Inhibitor Reduces Serum Prostatic Specific Antigen ( PSA ) Levels</brief_title>
	<detailed_description>Study Procedure - Male patient age 40 year old , LUTS least 3 month ( IPSS ≥ 8 ) , serum PSA level ≥ 4 ng/mL , without palpable prostatic nodule enrol prospective randomize trial investigate whether COX-2 inhibitor decrease serum PSA level act biomarker differentiate chronic inflammation prostate cancer . - Eligible subject randomly assign study control group 2:1 ratio . The study group receive doxazosin 4mg every day ( QD ) plus celecoxib 200mg QD 3 month control group receive doxazosin 4 mg QD 3 month . Patients investigated IPSS , total prostatic volume , transition zone index , maximum flow rate , void volume , postvoid residual , serum PSA , free PSA serum C-reactive protein ( CRP ) level baseline 3 month treatment . If serum PSA level remain high 4 ng/mL , patient either group advise receive prostatic biopsy histopathological investigation . - The prostatic biopsy advise end study group patient . Ten prostatic biopsied strip send pathological department investigate existence prostatic cancer . The two strip store liquid nitrogen investigation inflammatory biomarkers . Data Analysis - The efficacy evaluation perform intention-to-treat population ( ITT ) per-protocol population ( PPP ) datasets safety evaluation perform ITT datasets . The primary conclusion make primary endpoint secondary endpoint ITT population . Efficacy Endpoint Analysis - Net change efficacy item analyze paired t-test baseline post-treatment treatment group control group . The net change efficacy item analyze ANOVA test compare treatment group control group . The global assessment patient analyze chi-square test treatment control group . - All efficacy variable report respective point estimate 95 % confidence interval . Comparison test report respective p value . Safety Endpoints - Adverse event report controlled treatment group physiological system appropriate . Incidence adverse event category adverse event severity treatment analyze Cochran-Mantel-Haenszel test . The coding system use Coding Symbols Thesaurus Adverse Reaction Terms ( COSTART ) . Changes physical examination display individual system . - All statistical test use two-tailed α= 0.05 . Expected Results Conclusion - Chronic inflammation consider possible important factor induce LUTS promote prostatic growth . PSA elevation sensitive specific sign prostatic cancer . In order reduce need prostatic biopsy patient elevate serum PSA level , result study might provide simple way initial differential diagnosis chronic inflammation prostatic cancer . If serum PSA reduce significantly celecoxib therapy positive biopsy rate follow prostatic biopsy low control group , might use treatment initial management high PSA level men LUTS/BPH . Furthermore , chronic inflammation prostate reduce , bothersome LUTS well void condition might improve . This result another benefit men suffer LUTS worried surgical intervention .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Doxazosin</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Male adult age ≥ 40 year LUTS/BPH , IPSS ≥ 8 Free active urinary tract infection Free neurogenic void dysfunction No history previous prostate biopsy within 6 month No treatment BPH alphablocker 5alphareductase inhibitor within 6 month Patient legally acceptable representative sign write informed consent form Patients severe cardiopulmonary disease congestive heart failure , arrhythmia , poorly control hypertension , able receive regular followup Patients acute r chronic urinary retention urodynamically proven detrusor underactivity Patients postvoid residual &gt; 250 mL Patients laboratory abnormality screen include : 1 . Aspartate aminotransferase ( AST ) &gt; 3 x upper limit normal range 2 . Alanine aminotransferase ( ALT ) &gt; 3 x upper limit normal range 3 . Patients abnormal serum creatinine level &gt; 2 x upper limit normal range Patients serious disease condition consider investigator suitable entry trial Patients participate investigational drug trial within 1 month enter study</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Benign prostatic hyperplasia ( BPH )</keyword>
	<keyword>Lower urinary tract symptom ( LUTS )</keyword>
	<keyword>Prostatic specific antigen ( PSA )</keyword>
	<keyword>Cyclooxygenase-2 ( COX-2 )</keyword>
</DOC>